These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 20358440)

  • 21. Statistical issues of QT prolongation assessment based on linear concentration modeling.
    Tsong Y; Shen M; Zhong J; Zhang J
    J Biopharm Stat; 2008; 18(3):564-84. PubMed ID: 18470764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sevoflurane causes greater QTc interval prolongation in elderly patients than in younger patients.
    Nakao S; Hatano K; Sumi C; Masuzawa M; Sakamoto S; Ikeda S; Shingu K
    Anesth Analg; 2010 Mar; 110(3):775-9. PubMed ID: 20185656
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mixed models for data from thorough QT studies: part 1. assessment of marginal QT prolongation.
    Schall R; Ring A
    Pharm Stat; 2011; 10(3):265-76. PubMed ID: 21574242
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Measuring the effects of supratherapeutic doses of levofloxacin on healthy volunteers using four methods of QT correction and periodic and continuous ECG recordings.
    Noel GJ; Goodman DB; Chien S; Solanki B; Padmanabhan M; Natarajan J
    J Clin Pharmacol; 2004 May; 44(5):464-73. PubMed ID: 15102866
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Statistical models for heart rate correction of the QT interval.
    Ring A
    Stat Med; 2010 Mar; 29(7-8):786-96. PubMed ID: 20213712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of six commonly used QT correction models and their parameter estimation methods.
    Wang D; Taubel J; Arezina R
    J Biopharm Stat; 2012; 22(6):1148-61. PubMed ID: 23075014
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.
    Garnett CE; Beasley N; Bhattaram VA; Jadhav PR; Madabushi R; Stockbridge N; Tornøe CW; Wang Y; Zhu H; Gobburu JV
    J Clin Pharmacol; 2008 Jan; 48(1):13-8. PubMed ID: 18094216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Statistical analysis methods for QT/QTc prolongation.
    Ma H; Smith B; Dmitrienko A
    J Biopharm Stat; 2008; 18(3):553-63. PubMed ID: 18470763
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
    Stylianou A; Roger J; Stephens K
    J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Validation testing in thorough QT/QTc clinical trials.
    Tsong Y; Zhong J; Chen WJ
    J Biopharm Stat; 2008; 18(3):529-41. PubMed ID: 18470761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Is a thorough QTc study necessary? The role of modeling and simulation in evaluating the QTc prolongation potential of drugs.
    Rohatagi S; Carrothers TJ; Kuwabara-Wagg J; Khariton T
    J Clin Pharmacol; 2009 Nov; 49(11):1284-96. PubMed ID: 19734373
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Testing for positive control activity in a thorough QTc study.
    Zhang J
    J Biopharm Stat; 2008; 18(3):517-28. PubMed ID: 18470760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials.
    Sethuraman V; Sun Q
    Pharm Stat; 2009; 8(2):113-24. PubMed ID: 18481273
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Performance characteristics for some typical QT study designs under the ICH E-14 guidance.
    Hutmacher MM; Chapel S; Agin MA; Fleishaker JC; Lalonde RL
    J Clin Pharmacol; 2008 Feb; 48(2):215-24. PubMed ID: 18199896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation.
    Malik M; Hnatkova K; Batchvarov V
    Pacing Clin Electrophysiol; 2004 Jun; 27(6 Pt 1):791-800. PubMed ID: 15189536
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A maximum likelihood approach for estimating the QT correction factor using mixed effects model.
    Shah A; Hajian G
    Stat Med; 2003 Jun; 22(11):1901-9. PubMed ID: 12754723
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of vardenafil and sildenafil on cardiac repolarization.
    Morganroth J; Ilson BE; Shaddinger BC; Dabiri GA; Patel BR; Boyle DA; Sethuraman VS; Montague TH
    Am J Cardiol; 2004 Jun; 93(11):1378-83, A6. PubMed ID: 15165918
    [TBL] [Abstract][Full Text] [Related]  

  • 40. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
    Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
    J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.